Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pingkui enema
- Development stage
- Preclinical
- Administration
- Rectal
01
Overview
Pingkui enema is a traditional Chinese medicine (TCM) prescription that has been used clinically for many years to treat diarrhea and dysentery. It is currently being investigated for its therapeutic potential in ulcerative colitis (UC). The mechanism of action involves the regulation of gut probiotics, specifically increasing the abundance of *Bifidobacterium*, and modulating inflammatory cytokines by reducing pro-inflammatory factors such as tumor necrosis factor alpha (TNF-α) and interleukin-8 (IL-8), while increasing anti-inflammatory interleukin-13 (IL-13). Additionally, Pingkui enema appears to protect the intestinal mucosal barrier, as indicated by reduced serum levels of D-lactic acid (D-LA) and diamine oxidase (DAO).
02
Targets
IL-13 (Interleukin-13)IL8 (C-X-C Motif Chemokine Ligand 8)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on Pingkui enema.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pingkui enema.